Iohexol for Cancer

Phase-Based Progress Estimates
Dayton Physicians LLC - Troy, Troy, OHCancerIohexol - Drug
What conditions do you have?

Study Summary

This trial is testing whether iohexol can help doctors calculate the dose of carboplatin given to cancer patients.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 4 Secondary · Reporting Duration: Up to 4 weeks

Up to 4 weeks
Ability of markers in addition to creatinine in pre-treatment serum to better estimate kidney function in patients with cancer
Accuracy of achieving the targeted carboplatin area under the curve (AUC)
Bias of the formula for estimated glomerular filtration rate (eGFR) currently in existence in patients with cancer
Correlation between carboplatin clearance (CL) and mGFR
Divergence of eGFR from mGFR
Precision of achieving the targeted carboplatin AUC
Precision of the formula for eGFR currently in existence in patients with cancer
Relationship between carboplatin exposure and toxicity
Success rate of achieving the target carboplatin AUC in patients in whom the carboplatin dose is capped

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Treatment (iohexol, standard care carboplatin, blood samples)
1 of 1

Experimental Treatment

350 Total Participants · 1 Treatment Group

Primary Treatment: Iohexol · No Placebo Group · Phase 1

Treatment (iohexol, standard care carboplatin, blood samples)Experimental Group · 3 Interventions: Iohexol, Carboplatin, Biospecimen Collection · Intervention Types: Drug, Drug, Procedure
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved
Biospecimen Collection
Completed Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 4 weeks

Who is running the clinical trial?

NRG OncologyLead Sponsor
220 Previous Clinical Trials
95,415 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,153 Previous Clinical Trials
41,161,947 Total Patients Enrolled
Sarah E TaylorPrincipal InvestigatorNRG Oncology
1 Previous Clinical Trials
76 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are a male.

Frequently Asked Questions

How many participants are involved in the current clinical trial?

"This clinical trial necessitates 250 eligible participants, and recruiting is taking place in two centres - UPCI located in Pittsburgh, Pennsylvania; and Saint Louis Cancer & Breast Institute-Ballwin in Ballwin, New York." - Anonymous Online Contributor

Unverified Answer

Are there any precedents of research that have utilized Iohexol?

"Iohexol was initially investigated in 2002 at H Central de Asturias. Since then, 866 studies have been completed with 711 currently active experiments, many of which are conducted out of Pittsburgh, Pennsylvania." - Anonymous Online Contributor

Unverified Answer

What medical issues can Iohexol aid in alleviating?

"Iohexol is frequently administered to treat non-Hodgkin lymphoma, but it may also be utilized in the management of sarcoma and Hodgkin disease." - Anonymous Online Contributor

Unverified Answer

What potential hazards do patients face when taking Iohexol?

"Iohexol has been minimally studied, hence it received a score of 1 on our risk assessment scale. This is because this medical trial is in the early stages and lacks sufficient data to ensure safety." - Anonymous Online Contributor

Unverified Answer

Are there a plentiful number of medical centers conducting this trial in North America?

"This study is being conducted in various locations, including University of Pittsburgh Cancer Institute (UPCI) in Pennsylvania, Saint Louis Cancer and Breast Institute-Ballwin in New York, Memorial Sloan Kettering Cancer Center in Virginia, and a further 100 sites." - Anonymous Online Contributor

Unverified Answer

Are new participants being enrolled in this research project?

" reports that recruitment for this clinical trial is still ongoing, following its initial posting on November 18th 2019 and latest update from August 31st 2022." - Anonymous Online Contributor

Unverified Answer

What are the main goals of this medical experiment?

"The principal objective of this 4-week clinical trial is to discover the relationship between carboplatin clearance and mGFR. Secondary goals involve measuring the divergence of eGFR from mGFR, ascertaining how accurately target carboplatin AUCs can be reached among patients with elevated eGFR levels, and assessing if pre-treatment serum markers other than creatinine aid in providing an estimate for kidney function for cancer patients." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.